Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,425 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Left Ventricular Longitudinal Myocardial Function of Heart Failure Patients With Transition From Reduced to Preserved Ejection Fraction and of Those With Preserved Ejection Fraction.
Nagai S, Nishimori M, Kintsu M, Todo S, Ota E, Odajima S, Takeuchi K, Ichikawa Y, Yamauchi Y, Shiraki H, Yamashita K, Fukuda T, Hisamatsu E, Hirata KI, Tanaka H. Nagai S, et al. Circ Rep. 2024 Apr 13;6(5):161-167. doi: 10.1253/circrep.CR-24-0025. eCollection 2024 May 10. Circ Rep. 2024. PMID: 38736842 Free PMC article.
Correction: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.
Yamamoto Y, Yamauchi C, Toyama T, Nagai S, Sakai T, Kutomi G, Yoshimura M, Kawai M, Ohtani S, Kubota K, Nakashima K, Honma N, Yoshida M, Tokunaga E, Taira N, Iwata H, Saji S. Yamamoto Y, et al. Among authors: nagai s. Breast Cancer. 2024 May 12. doi: 10.1007/s12282-024-01589-z. Online ahead of print. Breast Cancer. 2024. PMID: 38735003 No abstract available.
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.
Yoshinami T, Nagai SE, Hattori M, Okamura T, Watanabe K, Nakayama T, Masuda H, Tsuneizumi M, Takabatake D, Harao M, Yoshino H, Mori N, Yasojima H, Oshiro C, Iwase M, Yamaguchi M, Sangai T, Kosaka N, Tajima K, Masuda N. Yoshinami T, et al. Among authors: nagai se. Breast Cancer. 2024 Apr 20. doi: 10.1007/s12282-024-01575-5. Online ahead of print. Breast Cancer. 2024. PMID: 38642245
Comparative evaluation of analytical pipelines for illumina short- and nanopore long-read 16S rRNA gene amplicon sequencing with mock microbial communities.
Ota Y, Yasunaga K, Mahazu S, Prah I, Nagai S, Hayashi T, Suzuki M, Yoshida M, Hoshino Y, Akeda Y, Suzuki T, Gu Y, Saito R. Ota Y, et al. Among authors: nagai s. J Microbiol Methods. 2024 Apr 8;221:106929. doi: 10.1016/j.mimet.2024.106929. Online ahead of print. J Microbiol Methods. 2024. PMID: 38599390
The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.
Yamamoto Y, Yamauchi C, Toyama T, Nagai S, Sakai T, Kutomi G, Yoshimura M, Kawai M, Ohtani S, Kubota K, Nakashima K, Honma N, Yoshida M, Tokunaga E, Taira N, Iwata H, Saji S. Yamamoto Y, et al. Among authors: nagai s. Breast Cancer. 2024 May;31(3):340-346. doi: 10.1007/s12282-024-01566-6. Epub 2024 Apr 3. Breast Cancer. 2024. PMID: 38570435 Free PMC article.
1,425 results